ClinicalTrials.gg
RecruitingNCT06663618Updated Oct 29, 2024

Short-term Glucocorticoid Combined with MMF for IgG4-RD

An interventional study of prednison and Mycophenolate mofetil in IgG4-related Disease, sponsored by Wen Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Wen Zhang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2023, registered Oct 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
14th of 37
63 · median 58
Started
2023
with 5 others
No phase
11 of 41
7 open now
Primary completion
2025-03
later than 5 of 27 live
Registered
24th of 41
by date
Lead sponsor
3 of 41
Wen Zhang

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 14th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2023, is one of 11 with no phase, reaches primary completion later than 5 of the 27 other live ones, and was the 24th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease

Read the detailed description

This is a monocenter, 72-week prospective, randomized controlled study to compare short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease.

03

Conditions studied

  • IgG4-related Disease

Keywords

  • IgG4-related disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 years old;
  2. All patients must meet the comprehensive diagnostic criteria of IgG4-RD revised in Japan in 2020 or the classification criteria of IgG4-RD formulated by ACR/EULAR in 2019;
  3. Active IgG4-RD (at least one organ has an IgG4-RD reaction score >=2 at the time of enrollment.);
  4. No previous medication or recurrence after withdrawal.

Exclusion criteria

Exclusion Criteria:

  1. Combined with other diseases as the main diagnosis.
  2. Pregnant or lactating women
  3. Patients with malignant tumor
  4. Active bacterial, fungal, viral or mycobacterial infections.
  5. Severe complications of important organs, and the expected survival time is less than 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Placebo comparator
    short-term glucocorticoid monotherapy

    Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.

    Drug: prednison

  • Experimental
    short-term glucocorticoid combined with Mycophenolate mofetil

    Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months. Oral Mycophenolate mofetil 0.75g bid for 6 months.

    Drug: prednison · Drug: Mycophenolate mofetil

Interventions

06

What researchers measure

Primary outcomes

  1. The difference of recurrent rate of IgG4-RD between the two groups

    Clinical recurrence definition: any item of IgG4-RD Responder Index \>=2 points; Recurrence of previously involved organs or involvement of new organs; With or without elevated serum IgG4 levels.

    Time frame: 72 weeks

Secondary outcomes

  1. The time of recurrence

    Clinical recurrence definition: any item of IgG4-RD Responder Index \>=2 points; Recurrence of previously involved organs or involvement of new organs; With or without elevated serum IgG4 levels.

    Time frame: 0-72 weeks

  2. The changes of IgG4-related disease Responder Index

    According to international multispecialty validation study of IgG4-related disease Responder Index (November, 2018), Responder Index ≥ 0, and higher scores mean a worse outcome.

    Time frame: 72 weeks

  3. The changes of serum IgG4 levels

    Level of serum IgG4(mg/dL)

    Time frame: 72 weeks

  4. The percentages of adverse events

    Adverse effect of drugs

    Time frame: 72 weeks

  5. The changes of PGA

    Changes of patient global assessment from baseline, score (0-10, higher is worse)

    Time frame: 72 weeks

  6. The difference of remission rate of IgG4-RD between the two groups

    Including complete remission rate, partial remission rate and total response rate.

    Time frame: 72 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Mar 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 29, 2024
StartActual
Sep 1, 2023
Primary completionEst.
Mar 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06663618
Lead sponsor
Wen Zhang
Responsible party
Wen Zhang (Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Oct 29, 2024
Start date
Sep 1, 2023
Primary completion
Mar 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Oct 29, 2024

Study contacts

Linyi Peng, MD
Contact
drpenglinyi@163.com
8615810395901
Wen Zhang, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mycophenolic Acid

Start the discussion